Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 4,448

Document Document Title
WO/2016/036954A1
The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defi...  
WO/2016/023877A1
The invention provides novel compounds having the general formula wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains com...  
WO/2016/010485A1
The present invention relates to compounds that are electron-deficient acceptors, donor- acceptor polymers that are synthesized from such electron-deficient acceptors, semiconductor devices synthesized from such donor-acceptor polymers a...  
WO/2016/008816A1
The present invention relates to herbicidal benzyloxy-substituted phenyl-diones and benzyloxy susbstituted phenyl-dioxo-thiazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such der...  
WO/2016/010950A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2016/007185A1
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, an...  
WO/2015/179697A1
Compounds and methods are provided for treating bacterial infections.  
WO/2015/177109A1
The invention relates to 5-(hetero)aryl-pyridazinones of general formula (I) as herbicides. In said formula (I), R1, R2, R3, R4, and R5 represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halog...  
WO/2015/177108A1
The invention relates to 5-(hetero)aryl-pyridazinones of general formula (I) as herbicides. In formula (I), R1, R2, R3, R4 and R5 represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. X1...  
WO/2015/171392A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q1, X, R1, R1a, R2 and R3, are as defined in the disclosure. Also disclosed are compositions containing the compounds o...  
WO/2015/170195A1
The present invention discloses to a sustained release pellets, delayed release pel- lets, multiple unit pellets systems (MUPS), multilayered tablets, osmotic tablets and delayed release tablets of Hydralazine hydrochloride pharmaceutica...  
WO/2015/168010A1
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein X is O, S or NR5; or X is C(R6)=C(R7), wherein the carbon atom bonded to R6 is also bonded to the carbon atom bonded to R4, and the c...  
WO/2015/164481A1
A multiphoton fluorescence anisotropy microscopy live cell imaging system and method to measure and map drug-target interaction in real lime at subcellular resolution. Proposed modality enables a direct measurement of drug/target binding...  
WO/2015/153720A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/140196A1
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to ...  
WO/2015/132427A1
The invention relates to pyridazin-3(2H)-one derivatives of general structure (I), (II) and (III), which are selective inhibitors of MAO-B, and to the use thereof for producing medicaments for treating disorders derived from the hyperact...  
WO/2015/125858A1
The present invention is a compound represented in formula (I-1) and the like, or a salt thereof. A harmful organism control agent and the like are obtained that contain at least one selected from the group consisting of the aforemention...  
WO/2015/117146A1
β-Substituted -amino acids, β-substituted γ-amino acid derivatives, and β-substituted γ-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted γ-amino acid derivatives and ...  
WO/2015/116786A1
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...  
WO/2015/108038A1
The present invention addresses the problem of providing: a compound which is useful for the prevention or treatment of hyperphosphatemia or a hyperphosphatemia-related disease, or a pharmacologically acceptable salt of the compound; and...  
WO/2015/106717A1
Disclosed are pyridazinone derivatives as represented by formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof. The present invention provides a series of pyridazinone derivatives that are easily synthesized and ha...  
WO/2015/103507A1
Described are RORϒ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...  
WO/2015/103508A1
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...  
WO/2015/095783A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2015/086523A1
A series of substituted heteroaromatic compounds containing two fused six- membered rings,tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; n...  
WO/2015/078374A1
The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as desc...  
WO/2015/072463A1
In the production of crops in agriculture, horticulture, and the like, damage by destructive insects is still great, and the development of novel agricultural/horticultural insecticides is desired due to the occurrence of destructive ins...  
WO/2015/067575A1
Compounds of the formula (I) : or a pharmaceutical salt thereof, wherein X, Ar1, R, R2, R3, R4, R5, R6 and R7 are as defined herein.. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammator...  
WO/2015/064532A1
The purpose of the present invention is to prevent or treat hyperphosphatemia or disease associated with hyperphosphatemia. To fulfill this purpose, a compound having general formula (I), or a pharmaceutically acceptable salt thereof, is...  
WO/2015/054572A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b...  
WO/2015/047134A1
The invention relates to medicine, and more particularly, but not exclusively, to compounds which exhibit wound-healing and/or repair activity. Proposed is bis(5-amino-1,4-dioxo-1,2,3,4-tetrahydrophthalazine-2-yl) zinc, a method for p...  
WO/2015/040425A1
A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or ...  
WO/2015/038660A1
Disclosed herein are pyridazinone compounds, pharmaceutical compositions that include one or more pyridazinone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease a...  
WO/2015/014230A1
The present invention relates to a matrix metalloproteinase inhibitor and a use thereof. In particular, the matrix metalloproteinase inhibitor has a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, and can...  
WO/2015/006100A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2014/206524A1
Compounds of the formula (I), in which R1, X and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervo...  
WO/2014/194667A1
The present invention relates to an alkynyl heterocyclic compound as represented by formula (I), a preparation method therefor, and uses thereof in the preparation of antitumor drugs.  
WO/2014/193951A1
Method for treating cardiac diseases using BET inhibitors including JQ1 are provided. Methods for treating cardiac hypertrophy, method for treating heart failure not arising from inflammation, methods for treating myocardial infarction, ...  
WO/2014/188863A1
A pyridazine compound represented by formula [1]: which is useful as an active ingredient of a plant disease control agent can be produced, by steps of obtaining a compound represented by formula [3]: by reacting a compound represented b...  
WO/2014/184503A1
The invention relates to dendritic compounds including a chelating, fluorochrome or recognition agent of formula (I), to compositions including same, and to the uses thereof, wherein in said formula (I): T, L1, D, R, L2, V and n are such...  
WO/2014/181788A1
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...  
WO/2014/170792A1
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...  
WO/2014/164704A2
Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.  
WO/2014/160440A1
The invention relates to a compound of Formula (I) and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof:  
WO/2014/157021A1
The compound expressed by formula (1) [in the formula, X represents a hydrogen atom, a fluorine atom, chlorine atom, or bromine atom, and Y represents a hydrogen atom, a fluorine atom, chlorine atom, or bromine atom] that is useful as a ...  
WO/2014/158943A1
The compositions and methods of described herein comprise novel ingredients effective to reduce unwanted pigmentation, such as skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented...  
WO/2014/151616A1
The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharma...  
WO/2014/150114A1
The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present i...  
WO/2014/152588A1
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.  
WO/2014/142273A1
According to the present invention, provided are a dihydropyridazine-3,5-dione derivative, a salt thereof, and solvates of the derivative and of the salt. Also provided are the following that contain any of said compounds as an active in...  

Matches 451 - 500 out of 4,448